InvestorsHub Logo
Followers 67
Posts 4832
Boards Moderated 0
Alias Born 06/12/2014

Re: None

Thursday, 03/30/2017 5:05:58 PM

Thursday, March 30, 2017 5:05:58 PM

Post# of 561
Catalyst Biosciences Announces Emergence from Key Patent Opposition Period Supporting Marzeptacog Alfa (activated), Catalyst’s Lead Clinical Program

European Patent Office indicates that no opposition to Catalyst’s patent has been filed --

-- INC Research selected as CRO for Phase 2/3 efficacy clinical trial of Factor VIIa, marzeptacog alfa (activated); trial expected to commence in the fourth quarter of 2017 --

SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., (NASDAQ:CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced receipt of notice from the European Patent Office that the opposition period for a patent granted to Catalyst has expired and no opposition has been filed.

http://ir.catalystbiosciences.com/phoenix.zhtml?c=254141&p=irol-newsArticle&ID=2257766
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CBIO News